Show simple item record

2023-02-25Rezension
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
dc.contributor.authorDahms, Karolina
dc.contributor.authorMikolajewska, Agata
dc.contributor.authorAnsems, Kelly
dc.contributor.authorMetzendorf, Maria-Inti
dc.contributor.authorBenstoem, Carina
dc.contributor.authorStegemann, Miriam
dc.date.accessioned2023-11-28T09:25:30Z
dc.date.available2023-11-28T09:25:30Z
dc.date.issued2023-02-25none
dc.identifier.other10.1186/s40001-023-01072-z
dc.identifier.urihttp://edoc.rki.de/176904/11390
dc.description.abstractBackground At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin‑1 (IL‑1) receptor antagonist Anakinra for the treatment of COVID‑19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of Anakinra in COVID‑19 remains unanswered, especially in patients receiving different forms of respiratory support. Therefore, the objective of this systematic review is to assess the safety and effects of Anakinra compared to placebo or standard care alone on clinical outcomes in adult hospitalized patients with SARS‑CoV‑2 infection. Methods We searched the Cochrane COVID‑19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, medRxiv, and the Cochrane Central Register of Controlled Trials (CCSR)) and the WHO COVID‑19 Global literature on coronavirus disease database to identify completed and ongoing studies from inception of each database to December 13, 2021. Since then, we monitored new published studies weekly up to June 30, 2022 using the CCSR. We included RCTs comparing treatment with Anakinra to placebo or standard care alone in adult hospitalized patients with SARS‑CoV‑2 infection. Results We included five RCTs with 1,627 patients (nAnakinra = 888, ncontrol = 739, mean age 59.63 years, 64% male). Random‑effects meta‑analysis was used to pool data. We found that Anakinra makes little or no difference to all‑cause mortality at up to day 28 compared to placebo or standard care alone (RR 0.96, 95% CI 0.64–1.45; RD 9 fewer per 1000, 95% CI 84 fewer to 104 more; 4 studies, 1593 participants; I2 = 49%; low certainty of evidence). Conclusions Anakinra has no effect on adult hospitalized patients with SARS‑CoV‑2 infection regarding mortality, clinical improvement and worsening as well as on safety outcomes compared to placebo or standard care alone. Trial Registration: PROSPERO Registration Number: CRD42021257552.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectAnakinraeng
dc.subjectInterleukin 1 receptor antagonist proteineng
dc.subjectSARS-CoV-2eng
dc.subjecthospitalizationeng
dc.subjectmeta-analysiseng
dc.subjectsystematic revieweng
dc.subjectCOVID-19eng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleAnakinra for the treatment of COVID-19 patients: a systematic review and meta-analysisnone
dc.typereview
dc.identifier.urnurn:nbn:de:0257-176904/11390-3
dc.type.versionpublishedVersionnone
local.edoc.container-titleEuropean Journal of Medical Researchnone
local.edoc.container-issn2047-783Xnone
local.edoc.pages12none
local.edoc.type-nameRezension
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://eurjmedres.biomedcentral.com/none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume28none
local.edoc.container-reportyear2023none
dc.description.versionPeer Reviewednone

Show simple item record